- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Farzad Mostashari, MD, Explains the Blue Button Initiative
Farzad Mostashari, MD, CEO, Aledade Inc, former National Coordinator for Health Information Technology, says that the Blue Button Initiative is a concept that allows patients to receive a copy of their own health information and use it however they like.
Farzad Mostashari, MD, CEO, Aledade Inc, former National Coordinator for Health Information Technology, says that the Blue Button Initiative is a concept that allows patients to receive a copy of their own health information and use it however they like. They can share their information with a 3rd party, or even use it to better manage their health and finances. The Blue Button Concept eases the flow of health information by creating a place where patients can access it online.
“We now have the biggest insurers in the country, the biggest pharmacies in the country, some of the biggest pharmaceutical manufacturers with the clinical trials,” Dr Mostashari says. “It’s basically become part of meaningful use that says if you want to be a doctor or hospital that gets the incentive payments or voids the penalties, you need to do this.”
He adds that the concept is “empowering patients” and “creating opportunities for innovation” by employing consumer technology that facilitates the improvement of patient health outcomes.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
